Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics Limited has appointed BDO Audit Pty Ltd as its new auditor, replacing William Buck Audit (VIC) Pty Ltd, effective January 6, 2025. This change aligns with the company’s status as a designated foreign issuer in Canada, requiring an auditor registered with the Canadian Accounting Board. The board’s decision reflects BDO’s global reach and expertise, aiming to enhance compliance and operational efficiency. The appointment will be ratified at the next Annual General Meeting, signaling a strategic move for Tryptamine in maintaining its regulatory obligations and potentially strengthening its market position.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited, a clinical-stage biopharmaceutical company, focuses on developing proprietary formulations of psilocin combined with psychotherapy to treat diseases with unmet medical needs. Its lead asset, TRP-8803, is an IV-infused formulation of psilocin designed to improve the efficacy and duration of psychedelic therapy. The company has conducted successful clinical trials for conditions like binge eating disorder and fibromyalgia, and is exploring treatments for irritable bowel syndrome.
YTD Price Performance: 5.00%
Average Trading Volume: 3,943,725
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$53.61M
See more data about TYP stock on TipRanks’ Stock Analysis page.